Engitix Therapeutics
Hendrik-Tobias Arkenau is the Executive Medical Director of the Sarah Cannon Research Institute UK (SCRI UK) and Clinical Lead for the Hospital Corporation of America International Cancer Service Line. Since founding the SCRI UK in 2010, he has built a portfolio of over 180 early-stage cancer clinical trials. He is a Fellow of the Royal College of Physicians.
This person is not in the org chart
This person is not in any offices
Engitix Therapeutics
To create a healthier future for patients with life-threatening diseases, Engitix Therapeutics is using its pioneering human extracellular matrix (ECM)-based discovery platform to develop a portfolio of programmes in fibrosis and solid tumors.